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Factor V was purified from the plasma of an activated protein C (APC)-resistant patient who is homozygous for the mutation Arg 506 Human blood coagulation factor Va is a heterodimeric glycoprotein (1) that consists of a heavy chain (M r ϭ 105,000) associated via a single Ca 2ϩ ion with a light chain (M r ϭ 74,000 or 72,000, cf. Ref 2) . Factor Va is formed during hemostasis from the inactive procofactor V after limited proteolysis. Factor Va is an essential nonenzymatic cofactor of the prothrombin-activating complex, which further comprises the serine protease factor Xa, calcium ions, and a procoagulant membrane surface. Depending on the reaction conditions factor Va accelerates prothrombin activation 10 3 -10 5 -fold (3) (4) (5) . Proteolytic inactivation of factor Va by activated protein C (APC), 1 is one of the key reactions in the regulation of thrombin formation. APC-catalyzed cleavage of factor Va is stimulated by the presence of negatively charged membrane surfaces (6 -8) and by the protein cofactor, protein S (8 -10) . The loss of cofactor activity of factor Va is associated with peptide bond cleavages in the heavy chain of factor Va at Arg 306 , Arg 506 , and Arg 679 (11, 12) . The physiologic importance of the down-regulation of factor Va activity by APC is underscored by the observation of recurrent thromboembolic events in individuals that are deficient in either protein C or protein S (13) (14) (15) .
Since a first publication by Dahlbäck et al. (16) , several laboratories have associated the occurrence of familial thrombophilia in a large group of patients with a poor anticoagulant response to APC (APC resistance). APC resistance is at least 10 times more common than all other known genetic thrombosis risk factors together and has an allelic frequency of ϳ2% in the Dutch population (17) . The molecular defect in APC-resistant patients was recently demonstrated (18 -21) to be linked to a single-point mutation in the factor V gene that causes an amino acid substitution (Arg 506 3 Gln) at a site that is cleaved during APC-catalyzed inactivation of factor Va (11) .
In this paper we present a kinetic analysis of APC-catalyzed inactivation of human factor Va that was either obtained from normal plasma or from the plasma of a patient who is homozygous for the mutation (Arg 506 3 Gln). Parallel experiments were performed in which changes of functional activity of factor Va during inactivation by APC were correlated with the cleavage of peptide bonds in the factor Va molecule. This study was undertaken in order to elucidate the consequences of the molecular defect in factor V for the regulation of in vivo prothrombin activation.
EXPERIMENTAL PROCEDURES
Materials-Hepes, Tris, bovine serum albumin, and Russel's viper venom were purchased from Sigma. DOPC and DOPS were obtained from Avanti Polar Lipids. The chromogenic substrates S2238 and S2366 were supplied by Chromogenix, Mölndal, Sweden. D-Pro-Phe-Arg-CH 2 Cl was obtained from Calbiochem and p-NPGB was from Nutritional Biochemicals. Micro BCA protein assay kits were from Pierce. Fast protein liquid chromatography equipment and column materials used for protein purification were purchased from Pharmacia, Uppsala, Sweden.
Proteins-Human coagulation factors used in this study were isolated from fresh frozen plasma. Human prothrombin and factor X were purified according to DiScipio et al. (22) . Human thrombin was prepared from prothrombin activation mixtures as described by Pletcher and Nelsestuen (23) . Human factor Xa was obtained from purified factor X after activation with RVV-X and isolation from the activation mixture by affinity chromatography on soybean trypsin inhibitorSepharose (24) . RVV-X was purified from Russel's viper venom according to Schiffman et al. (25) . Protein C was purified and activated as described by Gruber et al. (26) . The first steps of the preparation of human factor V and factor V R506Q were essentially as described by Dahlbä ck (27) with minor modifications (28) . The factor V (in 25 mM Hepes, pH 7.5, 50 mM NaCl, 5 mM CaCl 2 ) thus obtained was applied to a Resource S column and eluted with 20 ml of a linear gradient (50 -1000 mM NH 4 Cl) in 25 mM Hepes (pH 6.5), 5 mM CaCl 2 . Aliquots from column fractions were incubated for 15 min with 5 nM thrombin and factor Va-containing fractions were pooled. Factor Va was prepared by incubating factor V (33 g/ml) for 20 min with 5 nM thrombin in 25 mM Hepes (pH 7.5), 175 mM NaCl, and 5 mM CaCl 2 . After activation 15 nM D-Pro-Phe-Arg-CH 2 Cl was added to inhibit thrombin. Factor Va was further subjected to fast protein liquid chromatography on a Mono S column (HR 5/5) at room temperature (2) . The factor Va bound to the Mono S column was eluted with 15 ml of a linear gradient (50 -1000 mM NH 4 Cl) in 25 mM Hepes (pH 7.5), 5 mM CaCl 2 . Factor Va activity eluted from the column in two well-separated protein peaks containing factor Va with light chains of M r ϭ 74,000 and 71,000, respectively (2). The two factor Va containing peaks were pooled and brought into 25 mM Hepes (pH 7.5), 175 mM NaCl, 5 mM CaCl 2 by a buffer exchange on a PD-10 column. Factor V and factor Va from an APC-resistant patient were purified by the same methods. The patient was a female with a history of deep vein thrombosis and pulmonary embolism. Plasma from the patient was obtained by plasmapheresis. The APC-resistance ratio was 1.31 (Coatest APC-resistance kit, Chromogenix, Mölndal, Sweden). The patient was identified as homozygous for the substitution G 1691 3 A in the factor V gene (amino acid substitution Arg 509 3 Gln in factor V) by genetic analysis in genomic DNA samples isolated from peripheral blood (29) .
Protein Concentrations-Protein concentrations were determined with the micro BCA protein assay (30) . Molar thrombin and factor Xa concentrations were determined by active-site titration with p-NPGB (31, 32) . Prothrombin concentrations were determined after complete activation of prothrombin with Echis carinatus venom and quantitation of thrombin with p-NPGB. APC concentrations were determined with S2366 using kinetic parameters reported by Sala et al. (33) . Factor V and factor Va were quantitated as described below.
Phospholipid Vesicle Preparations-Small unilamellar phospholipid vesicles were prepared as described earlier (2) . Phospholipid concentrations were determined by phosphate analysis (34) .
Gel Electrophoretic and Immunoblot Analysis-Purity of protein preparations was analyzed by SDS-PAGE on 8% acrylamide slab gels (35) and staining with Coomassie Brilliant Blue R-250. The inactivation patterns of factor Va were analyzed after SDS-PAGE, electrophoretic transfer of proteins from the gel to Immobilon-P membranes, and visualization with a polyclonal rabbit-antibody directed against the heavy chain of factor Va and goat-anti-rabbit IgG conjugated with alkaline phosphatase as described by Blake et al. (36) .
Factor Va Assay-Factor Va cofactor activity was quantitated by determining the rate of factor Xa-catalyzed prothrombin activation in reaction mixtures that contained a limiting amount of factor Va, a saturating concentration factor Xa (5 nM), 50 M phospholipid vesicles (DOPS/DOPC, 10/90, mol/mol), and 0.5 M prothrombin (28) . Rates of prothrombin activation were determined with the chromogenic substrate S2238 (4). The molar factor Va concentration in the assay mixture was calculated from the rate of prothrombin activation using a turnover number of 6000 mol of prothrombin activated per min/mol of factor Xa-Va complex (37) . Factor V was quantitated by the same method after activation with 5 nM thrombin. Kinetic Data Analysis-The formation of a membrane-bound factor Xa-Va complex was determined by measuring rates of prothrombin activation in the presence of phospholipid vesicles at a fixed (limiting) concentration of factor Va and varying amounts of factor Xa. Factor Xa, factor Va, and phospholipid vesicles were preincubated for 5 min at 37°C in 25 mM Hepes (pH 7.5), 175 mM NaCl, 2 mM CaCl 2 , and 5 mg/ml BSA. Prothrombin activation was started by the addition of prothrombin (preincubated at 37°C in the same buffer) and rates of prothrombin activation were determined with the chromogenic substrate S2238 (4). The apparent K d for dissociation of the membrane-bound factor Xa-Va complex (K1 ⁄2Xa ) was obtained from plots of the rate of prothrombin activation as a function of the factor Xa concentration that were fitted to the equation for a single-site binding isotherm (hyperbola) via nonlinear least squares regression analysis.
The kinetic parameters (K m and V max ) for factor Xa-catalyzed prothrombin activation were determined by measuring the rate of thrombin formation at varying prothrombin concentrations in the presence of a fixed phospholipid concentration, a limiting amount of factor Xa, and a saturating concentration of factor Va as described in the previous paragraph. The kinetic parameters were obtained by fitting the data to the Michaelis-Menten equation using non-linear least squares regression analysis.
Curve Fitting of Pseudo-first Order Time Courses of Factor Va Inactivation-Time courses of factor Va or factor Va
R506Q inactivation by APC were determined by following the loss of cofactor activity of factor Va as a function of time. Data reported in the literature (11, 12) and in this paper demonstrate that the loss of factor Va cofactor activity can proceed via 2 pathways: 
in which Va t is the cofactor activity determined at time t, Va o is the cofactor activity determined before APC is added, B is the cofactor activity of factor Va int (expressed as fraction of the cofactor activity of native factor Va), and k 1 , k 2 , and k 3 are the rate constants defined above. The rate constants and the cofactor activity of factor Va int were obtained by fitting the data to Equation 3 using non-linear least squares regression analysis. In the case of normal factor Va inactivation, k 3 appeared to be associated with cleavage of the peptide bond at Arg 306 . Therefore, time courses of normal factor Va inactivation were fitted with a fixed k 3 , obtained from kinetic analysis of factor Va R506Q inactivation. In some experiments (factor Va inactivation in free solution) there was a slow loss of factor Va cofactor activity in the absence of APC. In these cases the spontaneous loss of cofactor activity (0.4%/min) was added to k 3 . . Fig. 1 represents a schematic diagram of the heavy chain of factor Va in which we have depicted the sites that are susceptible to APC and the molecular weights of possible cleavage products. In the present paper we will refer to the rate constants associated with the indicated peptide bond cleavages as k 306 , k 506 , and k 679 , respectively.
RESULTS

Peptide Bonds in Factor Va
Structural and Functional Properties of Factor Va
Purified from Normal and from APC-resistant Plasma-Factor V and thrombin-activated factor Va were purified from normal and homozygous APC-resistant plasma as described under "Experimental Procedures." The thrombin-activated factor Va and factor Va R506Q preparations had identical gel electrophoretic properties with the characteristic heavy chain with M r ϭ 105,000 and a light chain doublet at M r ϭ 74,000 and 71,000 (data not shown).
Factor Va and factor Va R506Q had similar cofactor activities in prothrombin activation. Kinetic analysis showed that prothrombin was activated in the presence of 25 M phospholipid vesicles (DOPS/DOPC, 10/90, mol/mol) with the following kinetic parameters: K m for prothrombin ϭ 0. Fig. 2 . At a low APC concentration (0.15 nM) normal factor Va was inactivated via a biphasic reaction during which 50% of the factor Va activity was lost within 3 min. Factor Va R506Q is inactivated at a considerably lower rate requiring more than 45 min for 50% loss of cofactor activity ( Fig. 2A) . When a similar experiment was performed at a high APC concentration (1.5 nM) inactivation of factor Va R506Q appeared to occur via a monophasic reaction (the data points could be fitted with a single exponential), whereas the inactivation of normal factor Va still proceeded via a biphasic reaction (Fig. 2B) .
The time courses of factor Va and Va R506Q inactivation (% factor Va activity versus time) were not affected by varying the concentrations of factor Va or Va R506Q between 0 and 5 nM. Since the rates of factor Va inactivation were also directly proportional to the amount of APC present (0.05-5 nM) we concluded that factor Va and Va R506Q inactivation were firstorder in both factor Va(Va R506Q ) and APC. This allows calculation of apparent second-order rate constants for factor Va inactivation from time courses such as shown in Fig. 2 .
On the basis of literature data (11, 12) and experiments presented below it can be postulated that the biphasic time courses of inactivation of normal factor Va presented in Fig. 2 The time courses of inactivation could indeed be fitted (Fig.  2, solid lines) using an equation that describes the time-dependent loss of cofactor activity when factor Va is inactivated via the random ordered two-step reaction model described under "Experimental Procedures." The fits of the particular experiment presented in Fig. 2 , and Arg 679 . The molecular weights of possible cleavage products correspond to those given in other publications (11, 12) .
FIG. 2. Inactivation of factor Va and factor Va
R506Q by APC in the presence of phospholipids. 0.3 nM purified human factor Va ( ) or factor Va R506Q (f) was incubated with (A) 0.15 nM APC or (B) 1.5 nM APC and 25 M phospholipid vesicles (DOPS/DOPC, 10/90, mol/mol) in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl 2 , and 5 mg/ml BSA at 37°C. At the indicated time points factor Va activity was determined as described under "Experimental Procedures." The solid lines represent exponential curves obtained after fitting the data using Equation 3 given under "Experimental Procedures." The rate constants and activity of the reaction intermediate were determined by nonlinear least-squares regression of the data.
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at UKB -Universiteit Maastricht on July 27, 2007 www.jbc.org Downloaded from factor Va R506Q inactivation was analyzed by SDS-PAGE, transfer to Immobilon-P membranes, and visualization of the reaction products with a polyclonal antibody directed against the heavy chain domain of human factor Va (Fig. 3) . In the description of the gel patterns presented below, the formation of reaction products was associated with peptide bond cleavages at Arg 306 , Arg 506 , or Arg 679 on the basis of molecular weights of heavy chain fragments indicated in Fig. 1 .
During the initial phase of inactivation of normal factor Va, reaction products with M r of 75,000 and 26,000/28,000 were formed, which is indicative of cleavage at Arg 506 (Fig. 3A) . Prolonged incubation of factor Va with a high APC concentration resulted in the disappearance of the M r ϭ 75,000 reaction intermediate (cleavage at Arg 306 ) and formation of reaction products with M r of 45,000 and 30,000, respectively. The fragment with M r ϭ 30,000 stains poorly with our polyclonal antibody and was hardly visible on the gel. During the final stage of the inactivation reaction the peptide bond at Arg 679 was also cleaved, as is indicated by the disappearance of the M r ϭ 26,000/28,000 doublet and the formation of low molecular weight products migrating with the dye front in the gel.
The immunoblot of the time course of APC-catalyzed inactivation of membrane-bound factor Va R506Q (Fig. 3B) 
APC-catalyzed Inactivation of Factor Va and Factor Va
R506Q
in the Absence of Phospholipids-In order to quantify the effect of the membrane on the peptide bond cleavages during factor Va and factor Va R506Q inactivation by APC we have also determined time courses of factor Va inactivation in the absence of phospholipids under pseudo-first order conditions (Fig. 4) . It was not possible to fit these time courses of inactivation with a single exponential. For both factor Va and factor Va R506Q it was necessary to postulate that inactivation proceeded via a biphasic reaction with a partially active reaction intermediate.
To correlate the loss of cofactor activity with peptide bond cleavages in the heavy chain we analyzed the product generation pattern by immunoblot analysis of samples taken from the inactivation mixture at selected time intervals (Fig. 5) . Compared with the peptide bond cleavage pattern of membranebound factor Va a striking difference was observed. In the absence of phospholipids cleavage at Arg 679 occurred at appreciable rates in factor Va R506Q (Fig. 5B) . This is concluded from the time-dependent appearance of an additional band in the heavy chain region of the gel.
Thus (Fig. 5A) indicates that during the time courses of normal factor Va inactivation (Fig. 4) only peptide bond cleavages at Arg 506 and Arg 306 significantly contributed to the loss of factor Va cofactor activity. Inspection of the immunoblot that represents inactivation of normal factor Va reveals that cleavage at Arg 679 had a minor contribution to the loss of factor Va cofactor activity. As a first approximation we have, therefore, also fitted this time course with a biphasic exponential. This fit (Fig. 4, solid line) inactivation by APC in the presence of phospholipids. A, 6 nM purified human factor Va and 1 nM APC; or B, 15 nM factor Va R506Q and 5 nM APC were incubated with 25 M phospholipid vesicles (DOPS/ DOPC, 10/90, mol/mol) in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl 2 , and 0.1 mg/ml BSA at 37°C. In the case of normal factor Va (A) the APC concentration was increased to 110 nM after 5 min. At the indicated time intervals samples from the inactivation mixture were subjected to SDS-PAGE. After transfer to Immobilon-P membranes, the heavy chain and derived fragments were visualized with a polyclonal antibody directed against the heavy chain of factor Va. The positions of the molecular weight markers are indicated at the left of panels A and B. The percentages cofactor activity at the indicated time points were (A) 100, 63, 46, 40, 25, 19, 17, and 0% and (B) 100, 80, 67, 43, 12, 3, 2, and 1%. Further experimental details are described under "Experimental Procedures." The data presented in Table I show that phospholipids stimulated the APC-catalyzed peptide bond cleavages in factor Va to a different extent. Phospholipids appeared to have no effect on k 679 R506Q (f) was incubated with 390 nM APC in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl 2 , and 5 mg/ml BSA at 37°C. At the indicated time points factor Va activity was determined as described under "Experimental Procedures." The solid lines represent exponential curves obtained after fitting the data using Equation 3 given under "Experimental Procedures." The rate constants and activity of the reaction intermediate were determined by nonlinear least-squares regression analysis of the data. and 500 nM APC were incubated in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl 2 , and 0.2 mg/ml BSA at 37°C. In the case of normal factor Va (A) the APC concentration was increased to 500 nM APC after 35 min. At the indicated time intervals samples from the inactivation mixture were subjected to SDS-PAGE. After transfer to Immobilon-P membranes, the heavy chain and derived fragments were visualized with a polyclonal antibody directed against the heavy chain of factor Va. ) that retained partial cofactor activity.
Inactivation of Factor Va and Factor
The actual cofactor activity of factor Va is dependent on its interaction with procoagulant membranes, factor Xa, prothrombin, and on its ability to increase the catalytic activity (k cat ) of factor Xa (2) (3) (4) (5) 40) . To examine which of these functions was impaired in factor Va that is cleaved at Arg 506 , we have characterized the functional properties of the inactivation intermediate. To this end normal factor Va was inactivated by APC in the absence of phospholipids (cf. Fig. 4 ) and after completion of the first phase of inactivation (Arg 506 cleavage) the reaction mixture was diluted and chromatographed on a Mono S column. The reaction intermediate bound to Mono S and eluted in a NH 4 Cl gradient as an overlapping doublet between 700 and 800 mM NH 4 Cl. These column fractions contained almost pure inactivation intermediate (Fig. 7B) .
To compare the abilities of factor Va and the purified inactivation intermediate to assemble with factor Xa into a membrane-bound prothrombinase complex we determined initial steady-state rates of prothrombin activation at limiting amounts of factor Va or factor Va cleaved at Arg 506 as a function of the factor Xa concentration (Fig. 7, A and B) . Low amounts of factor Xa were required for full expression of prothrombinase activity in the case of normal factor Va (K1 ⁄2Xa ϭ 0.088 nM). With factor Va that was cleaved at Arg 506 much higher factor Xa concentrations (K1 ⁄2Xa ϭ 3.9 nM) were needed to obtain maximal prothrombinase activity. 
FIG. 7. Cofactor activities of factor Va and factor Va cleaved at Arg
506
. Purified human factor Va (40 nM) was incubated with 15 nM APC in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl 2 , and 5 mg/ml BSA at 37°C. After 45 min the inactivation mixture was diluted 10-fold and applied to a Mono S column. Bound protein was eluted with 20 ml of a linear NH 4 Cl gradient (50 -1000 mM) in 25 mM Hepes (pH 7.5). Immunoblot analysis of factor Va (A) and the fraction eluting between 700 and 800 mM NH 4 Cl (B) is shown in the inset. Aliquots taken from the inactivation mixture after 0 min (native factor Va) and from the column fraction were used to determine rates of prothrombin activation at (A) 1.1 ng/ml factor Va ( ) or (B) 1.2 ng/ml factor Va cleaved at Arg 506 (f) in a reaction mixture containing 25 M phospholipid vesicles (DOPS/DOPC, 10/90, mol/mol), 0.5 M prothrombin, and varying concentrations of factor Xa in 25 mM Hepes (pH 7.5), 175 mM NaCl, 2 mM CaCl 2 , and 5 mg/ml BSA at 37°C. Rates of prothrombin activation were determined as described under "Experimental Procedures" and were corrected for thrombin formed in the absence of factor Va. The solid lines represent hyperbolas obtained after fitting the data with K1 ⁄2Xa ϭ 0.088 nM and V max ϭ 50.2 nmol of IIa/min/g of factor Va (k cat ϭ 151 s Ϫ1 ) for factor Va ( ) and K1 ⁄2Xa ϭ 3.9 nM and V max ϭ 28.7 nmol of IIa/min/g of protein (k cat ϭ 72 s Ϫ1 ) for the column fraction (factor Va cleaved at Arg 506 ) (f). Inset, double reciprocal plots of the same data.
since the K m values for prothrombin were virtually the same for prothrombinase complexes with normal and cleaved factor Va (data not shown).
From these data we conclude that APC-catalyzed cleavage at Arg 506 of the heavy chain of factor Va results in the formation of a reaction product that has lost part of its cofactor activity mainly because of a reduction of its affinity for factor Xa.
The Effect of the Factor Va Concentration and the Assay Conditions on Observed Time Courses of Inactivation of Membrane-bound Factor Va and Factor Va
R506Q by APC-The data presented in this paper demonstrate that differences in rate constants of cleavage at Arg 506 and Arg 306 are primarily due to differences in the K m for these peptide bond cleavages. This means that at high factor Va concentrations, where the rates of cleavage approach V max , differences in time courses of inactivation of factor Va and factor Va R506Q should become less pronounced.
We have also shown (Fig. 7) that the relative cofactor activities of native factor Va and factor Va cleaved at Arg 506 strongly depend on the factor Xa concentration present in the factor Va assay. It was demonstrated that factor Va that is cleaved at Arg 506 will exhibit much lower cofactor activity than native factor Va when assayed at factor Xa concentrations below K1 ⁄2Xa (3.9 nM).
These observations predict that the observed time courses of factor Va or factor Va R506Q inactivation by APC will depend: 1) on the factor Va concentration in the inactivation mixture and 2) on the assay conditions at which the loss of cofactor activity of factor Va is followed. Compared with factor Va R506Q , normal factor Va will be more rapidly inactivated at low than at high factor Va concentrations. The apparent loss of cofactor activity of normal factor Va will be even more rapid and approach complete loss of activity much faster when samples from the inactivation mixture are assayed at a factor Xa concentration at which the inactivation intermediate has no activity, i.e.
[factor Xa] Ͻ Ͻ 3.9 nM (K1 ⁄2Xa ).
These predictions were confirmed by an experiment in which time courses of factor Va inactivation were determined at low (Fig. 8A) or high concentrations of factor Va or Va R506Q (Fig.  8B ) and in which samples from the same inactivation mixture were assayed for the loss of cofactor activity in assay mixtures that contained a low (Fig. 8A) or a high factor Xa concentration (Fig. 8B) . As predicted, the differences in APC-catalyzed loss of cofactor activity of normal factor Va and factor Va R506Q were most pronounced when factor Va was inactivated at a low concentration and assayed in a prothrombin activation mixture that contained a low factor Xa concentration (Fig. 8A) . Differences in time courses of inactivation of factor Va and factor Va R506Q were indeed greatly reduced when high factor Va concentrations were inactivated by APC and the loss of cofactor activity was monitored in prothrombin activation mixtures that contained a high factor Xa concentration (Fig. 8B) ance of the M r ϭ 26,000/28,000 fragment or appearance of doublet bands in the heavy chain or the M r ϭ 54,000/56,000 region of immunoblots) is only observed after time intervals at which more than 90% of the cofactor activity of factor Va is already lost.
These data suggest that inactivation of membrane-bound factor Va and factor Va R506Q by APC proceeds via the pathways depicted below. R506Q verifies that the Michaelis-Menten kinetic parameters are indeed associated with the indicated peptide bond cleavages. These data suggest that the differences in rate constants for cleavage at Arg 506 and Arg 306 mainly result from differences in the K m and explain why at high factor Va concentrations (ϾK m ) differences between time courses of factor Va and factor Va R506Q inactivation are much less pronounced (Fig. 8B) .
APC can also fully inactivate factor Va and factor Va R506Q in the absence of a membrane surface (Fig. 4) since immunoblot analysis shows the appearance of a doublet band in the M r ϭ 105,000 region of the gel, which indicates that cleavage at position Arg 679 can already occur in the intact heavy chain. Comparison of rate constants obtained for free and membrane-bound factor Va shows that phospholipids greatly accelerate APC-catalyzed factor Va inactivation. Part of this stimulation will presumably be due to the fact that both the substrate (factor Va) and the enzyme (APC) bind to the membrane surface, a condition that promotes their interaction and reaction in a way similar to that of phospholipid-dependent coagulation factor activations (4, 5, 8, 40 -42) . However, in the case of APC-catalyzed factor Va inactivation, phospholipids do not accelerate the peptide bond cleavages to the same extent (Table I ). Cleavage at Arg 506 and Arg 306 in normal factor Va is stimulated 300 -600-fold, whereas cleavage at Arg 306 in factor Va R506Q is enhanced 1800-fold by phospholipids. This is indicative of a specific effect of phospholipids on APC-catalyzed cleavage at Arg 306 (cf. Refs. 11 and 12). We observed that k 679 is not significantly increased in membrane-bound factor Va. This demonstrates that after binding of factor Va to phospholipids the peptide bond at position Arg 679 is hardly accessible to cleavage by membrane-bound APC.
Taken together our conclusions seem to contradict earlier observations of Kalafatis et al. (11, 12) who reported that APCcatalyzed cleavages in the heavy chain of membrane-bound factor Va occur in an ordered, sequential fashion in which cleavage at Arg 506 promotes cleavage at Arg 306 and Arg 679 . They also suggested that cleavage at Arg 506 does not affect the cofactor activity of normal factor Va and that cleavage at position Arg 679 is required for full inactivation of factor Va. These apparent discrepancies may be explained by our observations that: 1) the relative rates of peptide bond cleavages in the heavy chain of factor Va depend on the factor Va concentration present in the inactivation mixture (Fig. 6) and 2 ) that the residual cofactor activity of partially active reaction intermediates strongly depends on the reaction conditions at which the functional activity of factor Va and its degradation products is assayed (Figs. 7 and 8 ). In this respect it is essential to mention that Kalafatis et al. (11, 12) collected their data at high factor Va concentrations (Ͼ200 nM) and used a factor Va assay system with high concentrations of coagulation factors, while our conclusions are based on experiments at low factor Va concentrations (Ͻ10 nM) and assessment of cofactor activity of factor Va in prothrombin activation mixtures that contained varying concentrations of coagulation factors.
To emphasize the importance of reaction and assay conditions, we demonstrated that the apparent loss of factor Va cofactor activity during in activation by APC indeed strongly depends on the concentration at which factor Va is inactivated and on the prothrombinase conditions at which the loss of cofactor activity is monitored (Fig.8) . Time courses of factor Va and factor Va R506Q inactivation at a high factor Va concentration, in which the loss of cofactor activity of factor Va is followed in prothombin activation mixtures that contain a high factor Xa concentration, show relatively little difference (Fig. 8B and Ref. 12) . However, when factor Va is inactivated at a low concentration and when its cofactor activity is assayed in a prothrombin activation mixture that contains a low amount of factor Xa, the differences between factor Va and factor Va R506Q are profound (Fig. 8A ). This observation may have significant physiological consequences. If thrombotic events result from ongoing coagulation at low concentrations of factor Xa and factor Va (the plasma factor V concentration is ϳ25 nM), downregulation of the cofactor activity of factor Va by APC will be most efficient in the case of normal factor Va and will be maximally impaired in case of factor Va
R506Q
. This underscores the increased risk for venous thromboembolism in individuals whose plasmas are APC-resistant as a consequence of a factor V phenotype in which Arg 506 is substituted by Gln.
